Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

INVO Fertility (IVF) EBITDA (2016 - 2025)

INVO Fertility (IVF) has disclosed EBITDA for 15 consecutive years, with -$1.6 million as the latest value for Q3 2025.

  • Quarterly EBITDA fell 25.88% to -$1.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$18.9 million through Sep 2025, down 210.52% year-over-year, with the annual reading at -$1.8 million for FY2024, 72.96% up from the prior year.
  • EBITDA for Q3 2025 was -$1.6 million at INVO Fertility, up from -$3.0 million in the prior quarter.
  • The five-year high for EBITDA was $5.7 million in Q4 2022, with the low at -$17.1 million in Q1 2025.
  • Average EBITDA over 5 years is -$1.8 million, with a median of -$1.8 million recorded in 2024.
  • The sharpest move saw EBITDA skyrocketed 344.64% in 2021, then tumbled 1049.64% in 2025.
  • Over 5 years, EBITDA stood at $4.4 million in 2021, then surged by 31.08% to $5.7 million in 2022, then crashed by 125.98% to -$1.5 million in 2023, then skyrocketed by 286.81% to $2.8 million in 2024, then crashed by 157.73% to -$1.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$1.6 million, -$3.0 million, and -$17.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.